Claimed effect · Survodutide

Does Survodutide help with body weight?

B
Grade B — probable, not settled1 phase 3 RCT + phase 2 · effect size: moderate
Short answerProbable, not settled. Human data exist (1 phase 3 RCT + phase 2) and mostly agree, showing a moderate effect — but too few, too small, or not yet peer-reviewed for a firm answer. SYNCHRONIZE-1, 725 adults, 76 weeks: −12% (3.6 mg) and −13% (6.0 mg) versus −5% placebo; at least 5% loss in 73%, 72% and 46%. Phase 2: up to −14.9% at 46 weeks.

What the studies show

SYNCHRONIZE-1, 725 adults, 76 weeks: −12% (3.6 mg) and −13% (6.0 mg) versus −5% placebo; at least 5% loss in 73%, 72% and 46%. Phase 2: up to −14.9% at 46 weeks.

“At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2% (95% confidence interval [CI], -13.6 to -10.8) in the 3.6-mg group, -13.0% (95% CI, -14.4 to -11.6) in the 6.0-mg group, and -5.4% (95% CI, -6.9 to -4.0) in the placebo group; 72.6%, 71.9% and 46.3% of the participants, respectively, had weight reduction of at least 5% (P<0.001 for all comparisons with placebo).”

Verbatim, from the abstractSurvodutide in adults with obesity: SYNCHRONIZE-1, a randomised, double-blind, placebo-controlled phase 3 trial. N Engl J Med, published online 7 June 2026

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Survodutide in adults with obesity: SYNCHRONIZE-1, a randomised, double-blind, placebo-controlled phase 3 trial.N Engl J Med, published online 7 June 2026725 adults, 76 weeks, 3.6 mg and 6.0 mg versus placebo.
  2. 2

In context

Survodutide is a once-weekly peptide that activates both the GLP-1 and glucagon receptors. In SYNCHRONIZE-1, a 725-person phase 3 trial published in June 2026, it produced 12–13% weight loss at 76 weeks against 5% on placebo, with gastrointestinal symptoms in up to 90% of participants. In people who also have type 2 diabetes the figure was 8–10% against 4% (SYNCHRONIZE-2, published October 2026). Its distinctive result is in the liver: a phase 2 trial resolved MASH without worsening fibrosis in 83% of patients at the top dose. It is not approved anywhere.

Survodutide is investigational. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Survodutide proven to help with body weight?
Not yet settled. 1 phase 3 RCT + phase 2 — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
SYNCHRONIZE-1, 725 adults, 76 weeks: −12% (3.6 mg) and −13% (6.0 mg) versus −5% placebo; at least 5% loss in 73%, 72% and 46%. Phase 2: up to −14.9% at 46 weeks.
Is Survodutide approved for this?
No. Survodutide is investigational; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Survodutide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →